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Introduction 
HEMATOPOIESIS  is  regulated  by  several  cytokines 
that  endorse  the  survival,  proliferation,  and 
differentiation  of  hematopoietic  stem  cells  and 
progenitor  cells.
1  Stem  Cell  Factor  (SCF)  plays  an 
important role in hematopoiesis, spermatogenesis, and 
melanogenesis.  Biological  effects  of  SCF;  as  a 
hematopoietic cytokine; is triggered by binding to its 
ligand c-kit.
2-4 The SCF gene is located on the Sl locus 
in  mice
4  and  on  chromosome  12q22-12q24  in 
humans.
5-6  SCF  can  exist  both  as  a  transmembrane 
protein and a soluble protein
7 (Figure 1, described in 
detail below). The both forms of SCF are produced by 
alternative  splicing  of  the  same  RNA  transcript  and 
depending  on  inclusion  or  exclusion  of  exon  6,  the 
proteolytic cleavage site can remain or not.
8-9 
Translation  of  mRNA  including  exon  6  contains 
proteolytic cleavage site and leads to production of the 
soluble  form  of  human  SCF  (SCF248).  Whereas  the 
transmembrane form of SCF (SCF220) is produced by 
alternative spliced mRNA  translation which  excludes 
exone  6  that  the  cleavage  occurs  after  Ala165.  Gly 
residue which is replace with amino acids 149-177 in 
SCF220.  
The soluble form of SCF is glycosylated and circulates 
as  a  dimer.  The  SCF's  soluble  form  has  noticeable 
secondary  structure  which  includes  a  helices  and  β 
sheets regions.
10-13 The molecular weight of the soluble 
form of SCF is about 18.5 kDa. SCF contains four Cys 
residues which construct the two intramolecular bonds 
Cys4-Cys89  and  Cys43-Cys138.
14-15  Deletion  of  the 
area  containing  Cys138  in  carboxyterminal  region 
reduces  biologic  activity  of  the  soluble  SCF.  This 
concept recommends that the Cys43- Cys138 disulﬁde 
bond might be essential for its full biologic activity.
16 
Subsequent  studies  show  that  both  intramolecular 
disulﬁde  pairs  are  important  to  retain  SCF  entire 
biologic activity.
17 
 
 
Figure 1. Soluble and transmembrane forms of human stem 
cell  factor  are  shown.  The  arrow  points  to  the  primary 
proteolytic  cleavage  site  of  SCF248  in  exon  6.  The 
transmembrane  form  of  SCF,  SCF220  lacks  the  primary 
proteolytic cleavage site in exon 6. Dotted lines show the 25 
amino  acid  signal  sequence  and  dark  box  indicates  the 
hydrophobic transmembrane domain. 
 
SCF has a great role in acceleration of hematopoietic 
stem cells entry into the cell cycle.
18 Colony forming 
unit- spleen CFU-S survival in vitro needs the presence 
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Purpose: Various cytokine regulates hematopoesis; they promote number of stages in 
stem cells biology such as proliferation, differentiation and endurance. Biological effects 
of SCF, as a hematopoietic cytokine; is triggered by binding to its ligand c-kit. Potential 
therapeutic applications of SCF include hematopoietic stem cell mobilization, exvivo 
stem/progenitor cell expansion, gene therapy, and immunotherapy. In this study we tried 
to  construct  of  pPIC9  recombinant  vector  containing  human  SCF.  Methods:  hSCF 
cDNA was amplified by PCR and both hSCF cDNA and pPIC9 as yeast expression 
vector (shuttle vector) digested by EcoR I and Xho I restriction enzymes. Subsequent the 
digestion  reaction,  ligation  reaction  was  carried  out.  In  order  to  verifying  of  pPIC9 
recombinant  vector  containing  hSCF,  PCR  and  sequence  analysis  was  performed. 
Results: The construction of recombinant expression vector of pPIC9 containing hSCF 
cDNA was confirmed by sequencing method successfully. Conclusion: rhSCF/pPIC9 
vector can be transformed into the Picha pastoris yeast as a eukaryotic host in order to 
produce human SCF at industrial scale.  
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of SCF, and when SCF accompanies with IL-3 in vitro, 
the production of CFU-S increases significantly along a 
two-week period.
19 
The  mast  cell  deﬁciency  in  W/Wv  and  Sl/Sld  mice 
indicated  that  SCF  might  be  necessary  for  mast  cell 
production.  Mast  cells  survival,  proliferation,  and 
maturation  are  promoted  by  SCF  in  vitro.  In  vitro 
proliferation and differentiation of pro-mastocyte, the 
earliest committed mast cell progenitor, occurs in the 
presence of both SCF and IL-3.
20 
In  according  to  mast  cell  studies,
7,21-23  hematopoietic 
cell lines studies
24,25 and of normal hematopoietic cells 
studies,
25 we can conclude that SCF can regulate the 
adhesive properties of hematopoietic cells. 
CD34
+  marrow  cells  adherence  to  ﬁbronectin  is 
enhanced  by  SCF  Exposure,  and  hematopoietic 
progenitor cells adhesion to stromal cells decreases in 
W/Wv mice.
26 
Sensitivity to radiotherapy changes in the presence of 
SCF. Sl and W mutations increases radiosensitivity in 
mice
27  it  might  be  due  to  the  capability  of  SCF  to 
suppress  apoptosis  and  promote  cell  cycle 
progression.
4,28 
According to the properties of SCF, this protein can be 
used in clinical applications. Thus production of human 
Stem  Cell  Factor  as  a  recombinant  protein  is  a 
necessity  in  our  country.  We  tried  to  construct 
recombinant shuttle  vector  of  pPIC9  contains  human 
stem  cell  factor  gene.  This  vector  can  be  used  for 
transformation into pichia pastoris yeast. The Figure 2 
shows the map of pPIC9. 
 
Figure 2. Expression vector used for production of recombinant  hSCF in Pichia pastoris. The hSCF cDNA nucleotide sequence in 
shown in details and sequences belong to primers which used in specific amplification of cDNA. Sequences found in the vector: 5’ 
AOX1-alcohol oxidase promoter, 3’AOX1(TT)- Transcriptional termination sequence,using 3’ AOX1– sequences for direct integration into 
the yeast genome, HIS4 –histidiol dehydrogenase codifying gene, S-secretion signal sequence, ColE1-Escherichia coli replication origin, 
Amp –ampicillin resistance gene in Escherichia coli. 
 
Materials and Methods 
PCR Amplification of hSCF cDNA 
The SCF cDNA sequence (protein coding nucleotides) 
was  amplified  by  PCR,  using  specific  primers), 
corresponding  to  the  N-  and  C-terminal  amino  acid 
sequence  of  SCF.  The  human  SCF  cDNA  sequence 
was derived from NCBI gene bank (Homo sapiens KIT 
ligand  (KITLG),  transcript  variant  b,  mRNA. 
ACCESSION  #  NM_000899).  Recognition  sites 
sequence of Xho1 and EcoR I restriction enzymes were 
added  to  5   ׳ ends  of  reverse  and  forward  primers  to 
introduce Xho I site at the 5’ and EcoR I site (Italics 
and  bold)  at  the  3’  end  of  the  PCR  products.  We 
included the sequence between Xho I site and SnaBI 
site (underlined) in the 5’ site of the SCF-fwd primer 
after  the  XhoI  recognition  site  sequence.  These  24 
nucleotides between Xho I site and SnaBI site which 
encodes the KEX2 and STE13 cleavage sites must be 
recreated in order for efficient cleavage of the fusion 
protein to occur. Meanwhile the stop codon (TAA) was 
included after the EcoR I site in reverse primer. The 
sequences  of  the  primers  were  5’-
ATCTCGAGAAAAGAGAGGCTGAAGCTGAAGG
GATCTGCAGG-3’  and  5’ 
AATGAATTCTTAGGCTGCAACAGGGGGTAACA
TAAATGG-3’.  
A 498 bp fragment including whole coding sequence of 
SCF gene was amplified with these primers by PCR in 
a  final  volume  50µl.  The  final  concentration  of 
materials  for  PCR  was  as  follows:  Primers:  0.4µM,  
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dNTP:  200µM  and  Mg2+:  1.5mM.  PFU  polymerase 
was used for amplification. Reaction was performed at 
an initial denaturation at 94 ºC for 3 min followed by 30 
cycles amplification, each cycle including denaturation 
for 30 sec, annealing at 68 ºC for 1 min and extension 
at 72 ºC for 1 min with an extra final 10 min incubation 
at 72 ºC to complete all extensions.  
 
Cloning  of  hSCF  cDNA  into  pPIC9  Expression 
Vector 
pPIC9 Vector and PCR product were double digested 
by  Xho1/EcoR1  enzymes  at  37  ºC  over  night 
(Fermentas) separately. Final volume of reaction was 
40  µl  and  tango  buffer  was  used  as  buffer  in  the 
reaction.  Following  electrophoresis  of  digested 
products, extraction of digested vector and insert from 
gel  agarose  was  performed  using  QIAGENE  kit. 
Ligation was performed with T4 DNA Ligase enzyme 
and  100ng  of  vector  with  the  ratio  1:3  of  insert  to 
vector. Following ligation, transformation to the DH5-α 
strain was performed by CaCl2 method. Transformant 
cells  were  plated  on  LB  Agar  containing  Ampicilin 
(50µl/ml)  and  incubated  overnight  at  37  ºC. 
Recombinant  plasmids  were  extracted  from  several 
clones by miniprep kit (Fermentas). 
 
Verifying  of  Recombinant  Vector  by  PCR  and 
Sequencing 
PCR  was  performed  at  the  same  conditions  on 
extracted  plasmids  with  SCF-Fwd  and  SCF-Rev 
primers. PCR product were analysed by sequencing. 
 
Results 
The SCF cDNA was amplified by PCR. A single band 
of the expected size (498 bp) corresponding to human 
SCF cDNA was detected by agarose gel electrophoresis 
(Figure 3). 
Double digestion of pPIC9 vector was performed with 
Xho1/EcoR1  restriction  enzymes.  Digested  products 
were resolved on agarose gel using electrophoresis and 
gel picture is presented in Figure 4. Following double 
digestion of vector by Xho1/EcoR, a small fragment of 
pPIC9 vector including 40 bp is separated which was 
electrophorsed out of gel and not observed on the gel. 
The bound A belongs to undigested vector and bounds 
B and C belong to digested vectors (Figure 4). 
Following Xho I/EcoR I digestion and purification of 
both  vector  and  PCR  product,  the  PCR  product  was 
ligated into the corresponding EcoR I and Xho I sites 
within the multi-cloning site (MCS) of pPIC9 plasmid. 
Subsequent  the  ligation  reaction,  bacterial 
transformation and Amp selection on LB agar plates, a 
few numbers of clones were obtained. A  total of 10 
bacterial clones were screened by PCR using the SCF-
Fwd  and  SCF-Rev  primers.  These  primers  yielded 
cloned  PCR  products  containing  the  498  bp  PCR 
product representing SCF cDNA (Figure 5). 
Sequence analysis of the 498 bp cloned PCR products 
confirmed SCF cDNA (Figure 6). 
 
 
Figure 3. Agarose gel electrophoresis of PCR products of SCF 
cDNA. Lane of (I) corresponds to PCR Product of human SCF 
cDNA. Lane (L) corresponds to 100bp Ladder (Fermentas). 
 
 
 
Figure 4. Double digestion of pPIC9 vector by Xho1/EcoR. 
bound A correspond to undigested vector. bound s B and C 
correspond  to  double  digested  pPIC9  vector.  Lane  L 
correspond to 10 Kbp ladder. 
 
 
Figure  5.  PCR  screening  of  cloned  SCF  cDNA  PCR 
products.  The  clones  on  Ampicillin  plates  were  picked  and 
screened  by  PCR.  Lane  L  corresponds  to  100  bp  ladder 
(Fermentas). Bound I represent bacterial clone containing the 
SCF cDNA PCR product.  
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Figure 6. Sequencing analysis of recombinant vector. A) Chromatogram of sequencing result related to SCF cDNA. B) Blast analysis 
of the sequencing result. The results reveal that 498 bp bond which obtained from PCR reaction which belongs to human SCF. 
 
This  approach  allowed  heterologous  gene  insertion 
between  the  5'  AOX1  promoter  sequence  and  the 
transcription  termination  sequence.  The  resultant 
plasmid  (rhSCF/pPIC9),  shown  in  Figure  1,  was 
transformed  into  Escherichia  coli,  enabling  rhSCF 
expression plasmid propagation.  
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Discussion 
The  survival,  differentiation,  and  mobilization  of 
numerous  cell  types  (myeloid,  erythroid, 
megakaryocytic, lymphoid, germ cell, and melanocyte 
progenitors) are promoted by SCF.
29,30 
SCF  is  widely  used  in  stem  cell  research  area  and 
purchasing this recombinant protein is costly and time-
consuming in Iran. Considering the cost and problem in 
accessibility of this product, clears the importance of 
indigenizing production of rhSCF.  
The  occurrence  of  multiple  disulfide  bridges  in  the 
native SCF protein (5) prompted us to use the Pichia 
pastoris  eukaryotic  expression  system,  since it  is 
known  that  disulfide  bridge  formation  of  eukaryotic 
proteins  expressed  in  prokaryotes  is  often  erratic, 
leading  to  improper  folding  and  tertiary  structure 
destabilization. 
For expression of SCF gene under the transcriptional 
control  of  AOX1  promoter,  a  498  bp  XhoI/EcoR  I 
fragment  composed  of  a  498-bp  region  beginning 
immediately  5’  of  methionine  initiator  ATG  of  SCF 
was generated by PCR.  
In designing primers for cloning SCF coding gene in 
pPIC9  vector,  we  attempted  to  clone  the  SCF  ORF 
under  control  of  AOX1  promoter  with  α-factor 
secretion signal sequence in downstream of the AOX1 
promoter.  Recent  evidences  suggest  that  the  a-factor 
secretion signal sequence might be modified to include 
KEX2-like  processing  sites  for  efficient  cleavage  to 
occur.
31 Choosing Xho I restriction site in the 5’-end 
allowed  in-frame  cloning  into  the  a-factor  secretion 
signal  of  pPIC9  expression  vector  and  a  sequence 
encoding  the  KEX2  and  STE13  cleavage  sites 
comprising  24  nucleotides  was  placed  ahead  of  the 
mature SCF cDNA. The reverse primer was designed 
based on the C-terminal amino acid sequence of SCF, a 
stop codon, and an EcoRI restriction site in the 3’-end. 
Using  these  primers,  the  498-bp  fragment  encoding 
hSCF  was  cloned  in  pPIC9  inframe  to  the  α-factor 
secretion  signal,  downstream  of  the  alcohol  oxidase 
promoter.  The  resultant  plasmid  (rhSCF/pPIC9)  was 
transformed into E. coli DH5α, purified, and analyzed 
by  sequencing,  confirming  the  presence  of 
rhSCF/pPIC9 expression plasmid.  
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